Glaxo to let Mylan make generic Paxil

All right, already. So says GlaxoSmithKline to Mylan Pharmaceuticals, which has been fighting the company's patent on extended-release Paxil, an antidepressant. Glaxo gave Mylan the patent licenses that allow it to sell Paxil ER beginning in October 2008. Mylan got FDA approval for its version of the drug in June, and it'll have 180-day exclusivity once it starts selling.

- see Mylan's press release
- check out the report from CNN Money

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.